Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand.
Respirology. 2010 Feb;15(2):194-201. doi: 10.1111/j.1440-1843.2009.01700.x.
Despite major advances in the understanding of the pathogenesis of asthma and improvements in management, the accompanying benefits from public health initiatives and clinical practice have arguably been less than expected. For example, there are no effective public health strategies or treatment regimes that reduce the risk of developing asthma or influence its natural history. These represent priority areas for future translational research, which would need to investigate genetic and environmental interactions and vaccine strategies. In terms of asthma management it is tempting to focus on novel drug therapies; however, a case can be made that the priority is to undertake research that leads to improvements in the use of existing treatments through public health and primary care initiatives. Guidelines represent an important component of this approach, with recommendations for asthma imbedded within respiratory guidelines that can be implemented in the developing world where other acute and chronic respiratory disorders are common. This approach offers the best opportunity to close the gap between what is currently achieved in asthma management and that which is potentially achievable.
尽管在哮喘发病机制的理解和管理方面取得了重大进展,但从公共卫生措施和临床实践中获得的益处却不尽如人意。例如,目前尚无有效的公共卫生策略或治疗方案可以降低哮喘发病风险或影响其自然病程。这些都是未来转化研究的优先领域,需要研究遗传和环境相互作用以及疫苗策略。在哮喘管理方面,人们很容易关注新型药物疗法;然而,也可以认为,当务之急是通过公共卫生和初级保健措施开展研究,改善现有治疗方法的应用。指南是这种方法的一个重要组成部分,哮喘的建议被纳入呼吸指南中,可以在其他急性和慢性呼吸系统疾病常见的发展中国家实施。这种方法为缩小当前哮喘管理水平与潜在可实现水平之间的差距提供了最佳机会。